Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
about
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityPaving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateLymphoma Immunotherapy: Current StatusMyeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor MicroenvironmentMyeloid-derived suppressor cells as therapeutic target in hematological malignanciesA method for identification and analysis of non-overlapping myeloid immunophenotypes in humansLymphoma: immune evasion strategiesClinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor CellsPrognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.Strategies for improving the reporting of human immunophenotypes by flow cytometry.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophagesBlood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphomaAbsolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphomaPrognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia.A novel subset of B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC.Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.Complexity and challenges in defining myeloid-derived suppressor cellsMyeloid-derived suppressor cells participate in preventing graft rejection.Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infectionIL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphomaIncreased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patientsAssociation of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sitesPrognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancerUtilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host diseaseIdentification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.The B7 homologues and their receptors in hematologic malignancies.Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs.Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells.Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.Myeloid-derived suppressor cell heterogeneity in human cancers.Immunological dysregulation in multiple myeloma microenvironment.Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion.
P2860
Q26773135-FC7CABA2-726D-4731-B37F-5F6F766A8D60Q26777205-E9529F7D-F5C9-4A10-9A90-BB129CAE4791Q26782902-F0C235D6-3939-4947-95D9-88CC0B1932ACQ26799126-7205F95D-5FC0-4565-9F88-1DD90A63EDEBQ27010234-C36054AC-AC31-4206-83E7-2CAA7670995CQ27310807-CDB13724-C68B-40B1-BC70-D618352C6298Q28080705-2EB9C205-123B-4396-AC6E-764453251E24Q28083973-420B6839-ACB3-448A-9967-DA2DD811360EQ31116522-D97B7A4A-9291-468E-9606-54EC2B65D596Q33759661-EA50934F-B6D1-4B6C-B60E-B20A0BE8EBF6Q33822690-D297BEB5-570C-4FCE-A18F-64F56878C90DQ34044797-51DA8C5B-44A9-4481-AB08-5F9A84CE7827Q34388117-C48ABD07-277E-45FF-A3CE-A00197C69EA4Q34626318-E0CB0711-AD5A-4127-B317-2DEF1D86EB96Q34798062-87BF1EED-109B-4EEC-BDDA-ACA050AE9496Q34882773-D8953E5C-A177-4265-8F95-5396EB5A05A8Q35042003-3547C3E0-AE15-4A3E-BF77-4E667BE4D464Q35506243-FCBB8494-6A31-404A-96D4-1D7D510D7DE4Q35506459-7EC53749-A1C1-4442-A766-BEC3265471E0Q35509317-D6640A09-F150-4476-A28A-CF882247D70BQ35852813-82F2A893-17BA-4F29-858E-4E1C71F94E72Q35912988-E1EAAC92-4A57-48DE-8920-3910CFF842F9Q35921894-756460B4-0154-43FB-8CF4-98FB82EF7205Q35965142-8A66C47E-F308-4610-8B92-802AB381D11FQ36206949-8E9F0DA7-2026-4416-B0F9-E61CD967F243Q36216198-88C3AC8F-99C6-4832-8FE2-311511A07A88Q36317453-741B133F-D5BD-4F4A-95E4-5D234A842F77Q36981510-895070FA-6A35-4AEF-B839-1548FAC57843Q37058110-0C8474F8-3ADA-4C8A-96F1-96E832056A37Q37094951-A1D5FEA0-9B08-45A9-B482-359957E707AFQ37317367-F606DDCC-ACF0-4510-86D5-F40B2A49F36EQ37863217-57445910-0922-4D2A-B70D-335D9B21E877Q37988965-CCA9F07F-A5DA-44F0-BA60-84B2306B2354Q38009278-2D81E50C-12EC-4DD6-90F9-D80DF5756E32Q38193589-797B319A-608D-450E-801C-C4A00A9D3420Q38207587-E6E09A1B-BFFA-4A2A-8314-326B3991F399Q38223250-29D8AFA9-1C13-4406-BC24-54BFE8B4C974Q38228353-205060E2-1788-43E6-AC18-B902EF8FEA02Q38269370-C0EEB549-F394-4998-B314-0137F5EB1436Q38344066-1732FA07-CDA3-4398-AE3B-9FD20A673E7B
P2860
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Immunosuppressive CD14+HLA-DR
@nl
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
@en
type
label
Immunosuppressive CD14+HLA-DR
@nl
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
@en
prefLabel
Immunosuppressive CD14+HLA-DR
@nl
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
@en
P2093
P2860
P1433
P1476
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
@en
P2093
Dennis A Gastineau
Michael P Gustafson
Peggy A Bulur
Thomas E Witzig
P2860
P304
P356
10.1182/BLOOD-2010-05-283820
P407
P577
2010-11-09T00:00:00Z